Novel use of tyrosine kinase inhibitor
OwnerMichael Welsh, Cecilia Annereninventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel use of a tyrosine kinase inhibitor or blocking agent. More precisely, it relates to use of an inhibitor of tyrosine kinase for production of a drug for prevention/treatment of type I diabetes mellitus, wherein the inhibitor is a GTK (BSK, IYK, FRK, RAK) tyrosine kinase. The invention also relates to use of FRK (or its equivalents) or the gene encoding the same, in an assay to screen for compounds interfering with FRK activity in pancreatic β-cells. Furthermore, the invention relates to a method of prevention/treatment of type I diabetes mellitus, comprising administration of an inhibitor against a FRK tyrosine kinase in pancreatic β-cells to type I diabetic patients.
Claims10
Use of an inhibitor of tyrosine kinase for production of a drug for prevention/treatment of type I diabetes mellitus, wherein the inhibitor is against a FRK tyrosine kinase in pancreatic β-cells.
Use of FRK (or its equivalents) or the gene encoding the same, in an assay to screen for compounds interfering with FRK activity in pancreatic β-cells.
Method of prevention/treatment of type I diabetes mellitus, comprising administration of an inhibitor against a FRK tyrosine kinase in pancreatic β-cells to type I diabetic patients.
Dependencies are inferred from the claim text.